{"disease":{"id":"lung-adenocarcinoma-stage-i","name":"lung adenocarcinoma stage i"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03199651","title":"Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":3584,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05830812","title":"Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00946712","title":"S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1333,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT06073431","title":"LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT03351842","title":"Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT04929041","title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","phase":"PHASE2, PHASE3","overall_status":"SUSPENDED","enrollment_count":427,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03391869","title":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":339,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02864992","title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":337,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00126581","title":"Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":188,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03110978","title":"Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04625647","title":"Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":116,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT04533451","title":"Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":101,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT07161713","title":"SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Barbara Nemesure","has_results":false},{"nct_id":"NCT05503667","title":"Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT05733000","title":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT03254004","title":"Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03845296","title":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT01386385","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05675033","title":"Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT06495125","title":"Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT07235280","title":"Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04201756","title":"Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT05198830","title":"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00334815","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":29,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01737502","title":"Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT04514497","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04263090","title":"Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT06982222","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03076164","title":"A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT04310943","title":"Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Zhou Chengzhi","has_results":false},{"nct_id":"NCT04183218","title":"Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes","phase":"","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02535325","title":"Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":36},"guidelines":[],"source":"Drug Landscape verified database"}